Transplantation Direct (Dec 2017)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection

  • Jennifer S. Husson, MD, MPH,
  • Bharath Ravichandran, PharmD, BCPS,
  • Srijana Jonchhe, PharmD, BCPS,
  • Shyamasundaran Kottilil, MD, PhD,
  • Eleanor Wilson, MD, MHS

DOI
https://doi.org/10.1097/TXD.0000000000000744
Journal volume & issue
Vol. 3, no. 12
p. e229

Abstract

Read online

Abstract. Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12).